Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

Similar articles for PubMed (Select 19280625)

1.

Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation.

Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK.

Cancer. 2009 Apr 15;115(8):1598-604. doi: 10.1002/cncr.24199.

2.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

3.

Preoperative genetic testing affects surgical decision making in breast cancer patients.

Lokich E, Stuckey A, Raker C, Wilbur JS, Laprise J, Gass J.

Gynecol Oncol. 2014 Aug;134(2):326-30. doi: 10.1016/j.ygyno.2014.05.028. Epub 2014 Jun 5.

PMID:
24910453
4.

Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.

Stolier AJ, Fuhrman GM, Mauterer L, Bolton JS, Superneau DW.

Breast J. 2004 Nov-Dec;10(6):475-80.

PMID:
15569201
5.

Preoperative risk assessment among women undergoing bilateral prophylactic mastectomy for cancer risk reduction.

Rueth NM, McMahon M, Arrington AK, Swenson K, Leach J, Tuttle TM.

Ann Surg Oncol. 2011 Sep;18(9):2515-20. doi: 10.1245/s10434-011-1642-2. Epub 2011 Mar 18.

PMID:
21424371
6.

Support needs and acceptability of psychological and peer consultation: attitudes of 108 women who had undergone or were considering prophylactic mastectomy.

Patenaude AF, Orozco S, Li X, Kaelin CM, Gadd M, Matory Y, Mayzel K, Roche CA, Smith BL, Farkas W, Garber JE.

Psychooncology. 2008 Aug;17(8):831-43. doi: 10.1002/pon.1279.

7.

Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.

Morgan D, Sylvester H, Lucas FL, Miesfeldt S.

Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z. Epub 2009 Apr 4.

PMID:
19347608
8.

Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.

Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J.

Genet Test Mol Biomarkers. 2009 Feb;13(1):51-6. doi: 10.1089/gtmb.2008.0067.

9.

One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).

Lodder LN, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Seynaeve C, van Geel AN, Tilanus MM, Bartels CC, Verhoog LC, Brekelmans CT, Burger CW, Niermeijer MF.

Breast Cancer Res Treat. 2002 May;73(2):97-112.

PMID:
12088120
10.

Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.

Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R.

Ann Intern Med. 2014 Feb 18;160(4):255-66. Review.

PMID:
24366442
11.

Risk management options elected by women after testing positive for a BRCA mutation.

Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, Raine-Bennett T, Powell CB.

Gynecol Oncol. 2014 Feb;132(2):428-33. doi: 10.1016/j.ygyno.2013.12.014. Epub 2013 Dec 16.

PMID:
24355485
12.

Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.

Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O.

Am J Obstet Gynecol. 2013 Apr;208(4):329.e1-6. doi: 10.1016/j.ajog.2013.01.026. Epub 2013 Jan 17.

PMID:
23333547
13.

Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.

Contant CM, Menke-Pluijmers MB, Seynaeve C, Meijers-Heijboer EJ, Klijn JG, Verhoog LC, Tjong Joe Wai R, Eggermont AM, van Geel AN.

Eur J Surg Oncol. 2002 Sep;28(6):627-32.

PMID:
12359199
14.

Prophylactic mastectomy for the prevention of breast cancer.

Lostumbo L, Carbine N, Wallace J, Ezzo J.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002748. Review. Update in: Cochrane Database Syst Rev. 2010;(11):CD002748.

PMID:
15495033
15.

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.

Kurian AW, Sigal BM, Plevritis SK.

J Clin Oncol. 2010 Jan 10;28(2):222-31. doi: 10.1200/JCO.2009.22.7991. Epub 2009 Dec 7.

16.

Surgical and financial implications of genetic counseling and requests for concurrent prophylactic mastectomy.

Murphy RX Jr, Adkinson JM, Namey T, Eid S, Bleznak A.

Ann Plast Surg. 2010 May;64(5):684-7. doi: 10.1097/SAP.0b013e3181dba8dc. Erratum in: Ann Plast Surg. 2010 Jul;65(1):116. Adkinson, Joshua M [added].

PMID:
20395792
17.
18.

Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.

J Clin Oncol. 2003 May 1;21(9):1675-81.

PMID:
12721241
19.

Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.

Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L.

Cancer. 2012 Jan 15;118(2):510-7. doi: 10.1002/cncr.26294. Epub 2011 Jun 29.

20.

Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations.

Kauff ND, Brogi E, Scheuer L, Pathak DR, Borgen PI, Hudis CA, Offit K, Robson ME.

Cancer. 2003 Apr 1;97(7):1601-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk